Plus Therapeutics Dividend

Dividend criteria checks 0/6

Plus Therapeutics hat in der Vergangenheit keine Dividende gezahlt.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.7%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$3.11
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating

Oct 07

Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end

Sep 22

Shareholders May Not Be So Generous With Plus Therapeutics, Inc.'s (NASDAQ:PSTV) CEO Compensation And Here's Why

May 11

Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract

May 04

Is Plus Therapeutics (NASDAQ:PSTV) Using Debt Sensibly?

Feb 23

Plus Therapeutics shows positive data for ReSPECT Phase 1 clinical trial in GBM

Nov 19

Stability and Growth of Payments

Fetching dividends data

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von PSTV in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von PSTV gestiegen sind.

Dividend Yield vs Market

Plus Therapeutics Dividend Yield vs Market

How does PSTV dividend yield compare to the market?
Segment	Dividend Yield
Company (PSTV)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.7%
Analyst forecast in 3 Years (PSTV)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von PSTV im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von PSTV im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Earnings Payout to Shareholders

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von PSTV, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Cash Payout to Shareholders

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da PSTV keine Ausschüttungen gemeldet hat.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Plus Therapeutics Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic

Plus Therapeutics Receives Non-Compliance Update from Nasdaq

Consensus revenue estimates fall by 34%

Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Plus Therapeutics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Insufficient new directors

Plus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.9375 million.

Plus Therapeutics, Inc. has filed a Follow-on Equity Offering.

Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting

Consensus revenue estimates fall by 28%

New major risk - Shareholder dilution

Plus Therapeutics, Inc. (NasdaqCM:PSTV) announces an Equity Buyback for $0.5 million worth of its shares.

Plus Therapeutics, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Plus Therapeutics, Inc. Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

Plus Therapeutics, Inc. Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase

Consensus revenue estimates increase by 21%

Plus Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Plus Therapeutics, Inc. Appoints Pius Maliakal as Vice President of Clinical Operations

Plus Therapeutics, Inc. Reports Positive Interim Updates from Two Respect Clinical Trials at SNMMI Annual Meeting

Price target decreased by 13% to US$46.50

Consensus revenue estimates increase by 21%, EPS downgraded

Consensus revenue estimates increase by 111%

Consensus revenue estimates fall by 42%

Plus Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Plus Therapeutics, Inc. Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases

Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

Plus Therapeutics Receives Second Letter from Nasdaq Regarding Minimum Bid Price Requirement

Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials

High number of new and inexperienced directors

Consensus revenue estimates increase by 50%

Plus Therapeutics to Provide Update on Respect(Tm) Clinical Trials At the 27Th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Plus Therapeutics, Inc. Announces Selection of Rhenium (186Re) Obisbemeda as International Non-Proprietary Name for 186RNL

Plus Therapeutics, Inc. to Report Q3, 2022 Results on Oct 20, 2022

Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating

Plus Therapeutics, Inc. Receives Product Development Research Grant by the Cancer Prevention and Research Institute of Texas

Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end

Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022

Plus Therapeutics, Inc. Announces Summary of FDA Meeting

Plus Therapeutics, Inc. (NasdaqCM:PSTV) announces an Equity Buyback for $2 million worth of its shares.

Plus Therapeutics, Inc. Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

Price target decreased to US$3.67

Plus Therapeutics GAAP EPS of -$0.24 misses by $0.02

Plus Therapeutics, Inc. to Report Q2, 2022 Results on Jul 21, 2022

Plus Therapeutics Completes Enrollment of Cohort 1 Respect-Lm Phase 1/2A Trial

Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting

Plus Therapeutics Receives Non-Compliance Notice from the Nasdaq Stock Market

Price target decreased to US$4.83

Price target decreased to US$5.17

High number of new and inexperienced directors

Plus Therapeutics, Inc. to Report Q1, 2022 Results on Apr 21, 2022

Plus Therapeutics, Inc., Annual General Meeting, May 16, 2022

Plus Therapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Price target decreased to US$5.67

Plus Therapeutics CEO Dr. Marc Hedrick - Cancer's Hardest Problems

Does Plus Therapeutics (NASDAQ:PSTV) Have A Healthy Balance Sheet?

Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT-GBM Trial

Plus Therapeutics to proceed with eighth cohort in ReSPECT glioblastoma trial

Shareholders May Not Be So Generous With Plus Therapeutics, Inc.'s (NASDAQ:PSTV) CEO Compensation And Here's Why

Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract

Revenue and earnings beat expectations

Full year 2020 earnings released: US$1.86 loss per share (vs US$2.77 loss in FY 2019)

Plus Therapeutics, Inc. Provides Update on Rhenium NanoLiposome (RNL™) Program

Is Plus Therapeutics (NASDAQ:PSTV) Using Debt Sensibly?

Plus Therapeutics, Inc. to Report Q4, 2020 Results on Feb 22, 2021

New 90-day high: US$3.13

Price target raised to US$6.42

New 90-day high: US$3.09

Plus Therapeutics, Inc Enters Master Services Agreement with Piramal Pharma Solutions, Inc

Plus Therapeutics, Inc. Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial

New 90-day low: US$2.04

Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center

New 90-day low: US$2.10

Plus Therapeutics, Inc. Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma

Plus Therapeutics shows positive data for ReSPECT Phase 1 clinical trial in GBM